drugset / Trial / NCT02260037
Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal
RandomizedParallel-groupOpen-labelTreatment
Summary
Safety, tolerability and pharmacokinetics
Timeline
- Start
- 2001-08
- Primary completion
- 2001-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epinastine | Small molecule | 0.035 mg | Intranasal |
| Subject | Epinastine | Small molecule | 0.42 mg | Intranasal |
Indications
No indication recorded.